Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.

about

Comparative molecular profiling of HPV-induced squamous cell carcinomas.

P2860

Q40193932-FC0DA5A7-DDA3-40B6-BD43-60B8CECE6E1F

P2860

Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.

Item

http://www.wikidata.org/entity/Q36860098

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Expression levels of ROS1/ALK/ ...... advanced biliary tract cancer.

@en

type

Item

label

Expression levels of ROS1/ALK/ ...... advanced biliary tract cancer.

@en

prefLabel

Expression levels of ROS1/ALK/ ...... advanced biliary tract cancer.

@en

P1476

Expression levels of ROS1/ALK/ ...... advanced biliary tract cancer.

@en

P2093

Chiun Hsu

http://www.w3.org/2001/XMLSchema#string

Hsiao-Hui Tsou

http://www.w3.org/2001/XMLSchema#string

Jen-Shi Chen

http://www.w3.org/2001/XMLSchema#string

Li-Tzong Chen

http://www.w3.org/2001/XMLSchema#string

Ming-Huang Chen

http://www.w3.org/2001/XMLSchema#string

Nai-Jung Chiang

http://www.w3.org/2001/XMLSchema#string

Shiu-Feng Huang

http://www.w3.org/2001/XMLSchema#string

Ta-Sen Yeh

http://www.w3.org/2001/XMLSchema#string

Yan-Shen Shan

http://www.w3.org/2001/XMLSchema#string

Yee Chao

http://www.w3.org/2001/XMLSchema#string

P2860

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

ROS1 rearrangements define a unique molecular class of lung cancers.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

P2888

srep25369

P304

25369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP25369

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27136744

http://www.w3.org/2001/XMLSchema#string

P921

cetuximab

P932

4853728

http://www.w3.org/2001/XMLSchema#string

Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.

about

P2860

P2860

Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P698

P921

P932